Fig. 4
PI3K inhibition decreases BRCA1/BARD1 expression and sensitizes tamoxifen-resistant cells to cisplatin. a, b The protein (a) and mRNA (b) expression of BARD1/BRCA1 in MCF7-Re cells treated with BKM120 or BYL719. c–f MCF7-Re cells were treated with control, BKM120, or BYL719 and then treated with cisplatin. The sensitivity to increasing concentrations of cisplatin (c), apoptotic cells (d), γH2AX expression (e), and DNA damage shown by comet assay (f) were measured. Scale bar indicated 100 μm. g–i MCF7-Re cells were treated with Dinaciclib and cisplatin. The sensitivity to increasing concentrations of cisplain (g), apoptotic cells (h), and γH2AX expression (i) were measured. In b–d, f–h, data show means ± s.d. (n = 3) **p < 0.01 compared with control by Student’s t test
